In particular, the combination of inhibitors of oncogenic BRAFV600 mutants (BRAFi) and MEK inhibitors (MEKi) achieves significant clinical responses in patients with BRAF-mutated melanoma [23,24]. Here, BRAF is linked to melanoma.